Genmab, a biotechnology company, agreed to acquire ProfoundBio, a clinical-stage biotechnology company, for $1.8bn. “The proposed acquisition of ProfoundBio firmly aligns with our long-term strategy and our ambitious 2030 vision, to impact the lives of patients through innovative antibody medicines. We believe that ProfoundBio’s ADC candidates, proprietary technology platforms and talented team will be a great addition to Genmab and that, together, we will be able to accelerate the development of innovative, differentiated antibody therapies for cancer patients," Jan van de Winkel, Genmab President and Chief Executive Officer.